Halted March 2021 — exploratory analyses suggested potential harm from non-allele-specific HTT lowering. Reframed the field around earlier intervention + allele-selective targeting.
Details
- nct_id
- NCT03761849
- phase
- phase_3
- status
- terminated
- domain
- huntingtons
- indication
- Manifest Huntington's Disease
- intervention
- Tominersen (antisense oligonucleotide targeting HTT)
- sponsor
- Roche
- n_enrolled
- 791
- primary_endpoint
- cUHDRS at 101 weeks
Raw fields (1)
- metadata
{}